Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
| Invent Farma / neuraxpharm Appoint New Group Chief Financial Officer | ||
| By: PR Newswire Association LLC. - 29 Mar 2017 | Back to overview list |
|
BARCELONA, Spain and DÜSSELDORF, Germany, March 29, 2017 /PRNewswire/ -- The combined Invent Farma/neuraxpharm (the "Group"), a leader in the specialty generics for CNS, has appointed Dr. Daniel Wiest as Group Chief Financial Officer ("CFO"). Dr. Wiest will assume the newly created role of Group CFO covering both Invent Farma and neuraxpharm. Dr. Wiest has more than 15 years' experience leading international companies with a proven track record on successfully implementing international growth strategies. He has 10 years' experience as CFO within private equity owned companies, including Wittur Group, KCA Deutag Group and APCOA Group. Stephan Walz, Global CEO of Invent Farma and neuraxpharm said "We welcome Daniel and we wish him great success in the deployment of his functions, which will be an important contribution to the further expansion of the Group." To learn more, visit: http://www.invent-farma.com and http://www.neuraxpharm.de About the Group Invent Farma / neuraxpharm Created in August 2016, following the acquisition by funds advised by Apax Partners, the Group Invent Farma / neuraxpharm is a leader in generic pharmaceutical products for the treatment of disorders of the central nervous system (CNS). The Group is the combination of the Barcelona-based Invent Farma with Düsseldorf-based neuraxpharm. Invent Farma has 50 years' experience in the development, manufacturing and marketing of pharmaceutical products, while neuraxpharm is a leading CNS brand that has earned the trust of specialist doctors, pharmacists and patients in over three decades. The Group markets, through Qualigen and neuraxpharm, generics drugs from a combined portfolio of predominantly differentiated products mainly in the CNS field. In addition, the Group owns and operates two manufacturing plants in Spain: one of the plants to produce active pharmaceutical ingredients ("APIs") with a unique expertise in the respiratory area (Inke), and the other one to produce finished dosage forms ("FDFs") across multiple therapeutic areas (Lesvi). 
|
||
|
|
||
 | Back to overview list | |